• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by KALA BIO Inc.

    2/16/24 4:11:52 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALA alert in real time by email
    SC 13G 1 KALA_SC13G_Feb24.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    KALA BIO, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE
    (Title of Class of Securities)

    483119202
    (CUSIP Number)

    FEBRUARY 9, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    483119202

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     135,096
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     135,096
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     135,096
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    483119202

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     135,096
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     135,096
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     135,096
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    483119202

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     135,096
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     135,096
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     135,096
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.0%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    483119202

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      KALA BIO, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    1167 Massachusetts Avenue
    Arlington, Massachusetts 02476

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.001 per share ("Common Stock")
     
      (e) CUSIP Number:
    483119202
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    483119202

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    483119202

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    483119202

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of February 15, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    483119202

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: February 15, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    483119202

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of KALA BIO, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: February 15, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $KALA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KALA

    DatePrice TargetRatingAnalyst
    3/30/2022Neutral → Underweight
    JP Morgan
    8/6/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    8/6/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $KALA
    Leadership Updates

    Live Leadership Updates

    See more
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever

      5/9/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

      ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Su

      3/29/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Financials

    Live finance-specific insights

    See more
    • Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

      ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The

      8/18/22 4:01:00 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov

      8/11/22 7:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

      ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se

      8/8/22 9:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Bazemore Todd

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      3/10/25 8:00:08 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Officer Brazzell Romulus K

      4/A - KALA BIO, Inc. (0001479419) (Issuer)

      1/10/25 8:00:36 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Bazemore Todd was granted 10,100 shares and sold $15,207 worth of shares (1,993 units at $7.63), increasing direct ownership by 10% to 91,147 units (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      1/7/25 8:14:03 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by KALA BIO Inc.

      SC 13G - KALA BIO, Inc. (0001479419) (Subject)

      11/14/24 4:49:42 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      7/8/24 8:54:55 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      6/28/24 4:11:51 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Neutral to Underweight

      3/30/22 7:39:31 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Kala Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously

      8/6/21 6:36:47 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Overweight to Neutral

      8/6/21 5:55:07 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      -- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of $51.2 million as of December 31, 2024, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies

      3/31/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

      ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. About KALA BIO, Inc. K

      2/26/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    SEC Filings

    See more

    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • KALA BIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - KALA BIO, Inc. (0001479419) (Filer)

      4/11/25 4:09:11 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by KALA BIO Inc.

      424B5 - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:45:34 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by KALA BIO Inc.

      10-K - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:03:08 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      12/31/24 4:00:18 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care